MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $302.42 Million Holdings in OR Royalties Inc. $OR

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of OR Royalties Inc. (NYSE:OR) by 39.2% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 7,543,667 shares of the basic materials company’s stock after purchasing an additional 2,124,421 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.’s holdings in OR Royalties were worth $302,419,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of OR. Caitlin John LLC acquired a new stake in shares of OR Royalties during the third quarter worth $78,000. Eagle Global Advisors LLC acquired a new position in OR Royalties in the third quarter valued at $206,000. Merit Financial Group LLC acquired a new position in OR Royalties in the third quarter valued at $215,000. Flow Traders U.S. LLC bought a new stake in OR Royalties during the third quarter valued at $217,000. Finally, Smith Salley Wealth Management bought a new stake in OR Royalties during the third quarter valued at $228,000. Institutional investors and hedge funds own 68.52% of the company’s stock.

Analysts Set New Price Targets

OR has been the subject of several research analyst reports. Wall Street Zen lowered OR Royalties from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 21st. Scotiabank upped their target price on OR Royalties from $41.00 to $51.00 and gave the company a “sector perform” rating in a research report on Monday, January 26th. Canadian Imperial Bank of Commerce reaffirmed an “outperform” rating on shares of OR Royalties in a research note on Wednesday, February 4th. Weiss Ratings reiterated a “buy (b)” rating on shares of OR Royalties in a report on Monday, December 29th. Finally, Zacks Research raised OR Royalties from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 4th. Two investment analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $38.25.

OR Royalties Stock Performance

Shares of OR Royalties stock opened at $40.22 on Tuesday. The stock has a market capitalization of $7.55 billion, a PE ratio of 36.90 and a beta of 0.75. OR Royalties Inc. has a 52 week low of $18.99 and a 52 week high of $48.06. The stock has a 50 day moving average price of $42.55 and a two-hundred day moving average price of $37.81.

OR Royalties (NYSE:OR) last issued its earnings results on Wednesday, February 18th. The basic materials company reported $0.32 earnings per share for the quarter, topping analysts’ consensus estimates of $0.31 by $0.01. OR Royalties had a return on equity of 12.73% and a net margin of 74.30%.The company had revenue of $90.47 million for the quarter, compared to analyst estimates of $90.80 million. Research analysts forecast that OR Royalties Inc. will post 0.62 EPS for the current year.

OR Royalties Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 15th. Shareholders of record on Tuesday, March 31st will be issued a dividend of $0.055 per share. The ex-dividend date is Tuesday, March 31st. This represents a $0.22 annualized dividend and a yield of 0.5%. OR Royalties’s dividend payout ratio is presently 20.18%.

About OR Royalties

OR Royalties PLC (NYSE: OR) is a closed-ended investment company that specializes in acquiring and managing royalty interests in life science and pharmaceutical products. The company provides capital to biotechnology, specialty pharmaceutical and medical device companies in exchange for a share of future sales revenues. By focusing on royalties secured against marketed products, OR Royalties aims to deliver income and growth potential while minimizing the development and commercialization risks typically associated with direct equity stakes.

The company’s core activities include sourcing royalty transactions, structuring bespoke financing solutions and actively monitoring a diversified portfolio of assets.